Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer

Keywords

NSCLC / activating EGFR-mutations / first-line treatment / TKIs / cost of drugs

References

[1] Takeda M.First- and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-positive non-small cell lung cancer?.Int J Mol Sci2019;20:146 PMCID:PMC6337322

[2] Giuliani J.The economic impact of biosimilars in oncology and hematology: the case of Trastuzumab and Rituximab.Anticancer Res2019;39:3971-3

[3] Aguilar-Serra J,Pastor-Clerigues A.Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis.J Comp Eff Res2019;8:853-63

[4] Cherny NI,Dafni U.A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).Ann Oncol2015;26:1547-73

[5] Giuliani J.Which grade is of clinical benefit in the randomised controlled trials?.Eur J Cancer2018;104:233-5

[6] Zhou C,Chen G.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.Lancet Oncol2011;12:735-42

[7] Rosell R,Gervais R.Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia ToracicaErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.Lancet Oncol2012;13:239-46

[8] Mok TS,Thongprasert S.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med2009;361:947-57

[9] Maemondo M,Kobayashi K.North-East Japan Study GroupGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.N Engl J Med2010;362:2380-8

[10] Mitsudomi T,Yatabe Y.West Japan Oncology GroupGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.Lancet Oncol2010;11:121-8

[11] Han JY,Kim SW.First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.J Clin Oncol2012;30:1122-8

[12] Sequist LV,Yamamoto N.Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.J Clin Oncol2013;31:3327-34

[13] Wu Y,Hu CP.Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.Lancet Oncol2014;15:213-22

[14] Soria JC,Vansteenkiste J.FLAURA InvestigatorsOsimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.N Engl J Med2018;378:113-25

[15] Fukuoka M,Thongprasert S.Biomarker analyses and final overall survival results from a phase III, Randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).J Clin Oncol2011;29:2866-74

[16] Ramalingam SS,Planchard D.FLAURA InvestigatorsOverall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC.N Engl J Med2020;382:41-50

[17] Hofmarcher T,Wilking N.The cost of cancer in Europe 2018.Eur J Cancer2020;129:41-9.

[18] Azimi NA.The effectiveness of cost-effectiveness analysis in containing costs.J Gen Intern Med1998;13:664 PMCID:PMC1500894

[19] Giuliani J.Financial toxicity and non-small cell lung cancer treatment: the optimization in the choice of immune check point inhibitors.Anticancer Res2019;39:3961-5

[20] Giuliani J.Immunotherapy in first-line for advanced non-small cell lung cancer: a cost-effective choice?.Recenti Prog Med2019;110:138-43

[21] Giuliani J.Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) level.Oral Oncol2019;97:143-5

[22] Giuliani J.Nivolumab in second-line treatment for advanced non-small-cell lung cancer with squamous-cell histology: a perspective based on pharmacologic costs.Clin Lung Cancer2017;18:e363-5

[23] Giuliani J.Nivolumab is a cost-effective second-line treatment for metastatic renal-cell carcinoma.Clin Genitourin Cancer2018;16:e557-62

[24] Giuliani J,Ponturo G.Economic sustainability of nivolumab at flat dose for second-line treatment of metastatic non-small cell lung cancer in real life.J Oncol Pharm Pract2019;25:2059-60